Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002974 · ClinicalTrials.gov registry record · Phase 2
Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00002974: Completed Phase 2 study, sponsored by University of Wisconsin, Madison.
NCT00002974 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002974, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with whole-body hyperthermia may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of whole-body hyperthermia plus combination chemotherapy in treating patients who have advanced sarcoma that is metastatic or that cannot be surgically removed.
Interventions
- DRUG carboplatin
- DRUG etoposide
- DRUG ifosfamide
- PROCEDURE hyperthermia treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1996-07 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
What the finished NCT00002974 record still lists
NCT00002974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00002974 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002974 about?
NCT00002974 is a clinical study titled "Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma". RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with whole-body hyperthermia may kill more tumor cells. PU...
What is the current status of trial NCT00002974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 1996-07. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00002974?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), ifosfamide (DRUG), hyperthermia treatment (PROCEDURE).
Who is sponsoring clinical trial NCT00002974?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002974's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia